Reduction in HER-2 protein expression in a breast tumor HER-2 positive after only one injection of Trastuzumab: A case report

Cases Journal

Volumn 2, Issue 6, 2009, Pages

  Elghissassi, Ibrahim ^a   Inrhaoun, Hanane ^a   Vignot, Stephane ^b   Mrabti, Hind ^a   Errihani, Hassan ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

AGED; ARTICLE; BREAST ADENOCARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; PARTIAL MASTECTOMY; PROTEIN EXPRESSION; RECTUM CARCINOMA;

EID: 77953471682     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.4076/1757-1626-2-8099     Document Type: Article

References (11)

1. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998, 16:413-428.
2. Quenel N, Wafflart J, Bonichon F et al.: The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995, 35:283-291.
3. Slamon DJ, Clark GM, Wong SG et al.: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
4. Simon R, Nocito A, Hubscher T et al.: Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001, 93:1141-1146.
5. Pauletti G, Dandekar S, Rong H et al.: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000, 18:3651-3664.
6. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 120: 719-726.
7. Gong Y, Booser DJ, Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005, 103:1763-1769.
8. Guarneri V, Giovannelli S, Ficarra G et al.: Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008, 13:838-844.
9. Kyoda S, Kinoshita S, Takeyama H et al.: HER-2 protein overexpression in metastatic breast carcinoma found at autopsy. Jpn J Clin Oncol 2008, 38:743-747.
10. Pothos A, Plastira K, Plastiras A et al.: Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/ neu oncogene in archival material of breast carcinoma. Acta Histochem Cytochem 2008, 41:59-64.
11. Dowsett M, Bartlett J, Ellis IO et al.: Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003, 199:418-423.